Skip Navigation

Nephrology Dialysis Transplantation 2009 24(9):i; doi:10.1093/ndt/gfp412
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


In this issue

The first 10% of the full text of this article appears below.

A French dialysis cohort study explored the factors associated with elevated serum FGF-23 levels in patients treated with long haemodialysis sessions (3 x 5–8 hours per week). This study demonstrated a high level of circulating FGF-23 in these patients, despite infrequent hyperphosphataemia. The authors further confirmed the association of higher serum FGF-23 levels with mortality and vascular calcification, regardless of the serum phosphate levels.

An accompanying editorial comment further scrutinizes these observations putting them into a broader perspective.

See article by Jean et al., pages 2792–2796 and editorial comment by Ketteler and Biggar, pages 2618–2620

Two clinical studies address the issue of preservation of residual renal function (RRF) in peritoneal dialysis (PD) patients. One study identified factors associated with renal . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?